Table of Content

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Number of Kidney Cancer Cases
4.2.2 Increased R&D Expenditure of Pharmaceutical Companies
4.3 Market Restraints
4.3.1 High Cost Associated with Treatment
4.3.2 Preference for Generic Drugs
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Cancer Type
5.1.1 Renal Cancer Carcinoma
5.1.2 Clear Cell Renal Cell Carcinoma
5.1.3 Papillary Renal Cell Carcinoma
5.1.4 Chromophobe Renal Cell Carcinoma
5.1.5 Other Cancer Types
5.2 By Therapeutic Class
5.2.1 Targeted Therapy
5.2.2 Immunotherapy
5.3 By Pharmacologic Class
5.3.1 Angiogenesis Inhibitors
5.3.2 Monoclonal Antibodies
5.3.3 mTOR Inhibitors
5.3.4 Cytokine Immunotherapy (IL-2)
5.4 By Diagnostics
5.4.1 Biopsy
5.4.2 Intravenous Pyelogram
5.4.3 CT Scan
5.4.4 Nephro-Ureteroscopy
5.4.5 Ultrasound
5.4.6 Other Diagnostics
5.5 Geography
5.5.1 Asia-Pacific
5.5.1.1 China
5.5.1.2 Japan
5.5.1.3 India
5.5.1.4 Australia
5.5.1.5 South Korea
5.5.1.6 Rest of Asia-Pacific


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bayer AG
6.1.2 F. Hoffmann-La Roche Ltd
6.1.3 Eisai.co.Ltd
6.1.4 Novartis AG
6.1.5 Pfizer Inc
6.1.6 Abbott Laboratories
6.1.7 Amgen Inc
6.1.8 Seattle Genetics


7 MARKET OPPORTUNITIES AND FUTURE TRENDS